 Glucagon-Like Peptide 1
"Glucagon-Like Peptide 1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A peptide of 36 or 37 amino acids that is derived from PROGLUCAGON and mainly produced by the INTESTINAL L CELLS. GLP-1(1-37 or 1-36) is further N-terminally truncated resulting in GLP-1(7-37) or GLP-1-(7-36) which can be amidated. These GLP-1 peptides are known to enhance glucose-dependent INSULIN release, suppress GLUCAGON release and gastric emptying, lower BLOOD GLUCOSE, and reduce food intake.
| Descriptor ID |
D052216
|
| MeSH Number(s) |
D06.472.317.469.500.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Glucagon-Like Peptide 1".
Below are MeSH descriptors whose meaning is more specific than "Glucagon-Like Peptide 1".
This graph shows the total number of publications written about "Glucagon-Like Peptide 1" by people in this website by year, and whether "Glucagon-Like Peptide 1" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 | | 2000 | 0 | 1 | 1 | | 2005 | 1 | 0 | 1 | | 2008 | 1 | 1 | 2 | | 2009 | 2 | 1 | 3 | | 2010 | 2 | 1 | 3 | | 2011 | 3 | 3 | 6 | | 2012 | 2 | 0 | 2 | | 2013 | 3 | 3 | 6 | | 2014 | 7 | 2 | 9 | | 2015 | 3 | 3 | 6 | | 2016 | 1 | 2 | 3 | | 2017 | 3 | 2 | 5 | | 2018 | 1 | 0 | 1 | | 2019 | 3 | 4 | 7 | | 2020 | 4 | 1 | 5 | | 2021 | 1 | 1 | 2 | | 2022 | 2 | 3 | 5 | | 2023 | 1 | 4 | 5 | | 2024 | 2 | 1 | 3 | | 2025 | 2 | 12 | 14 | | 2026 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Glucagon-Like Peptide 1" by people in Profiles.
-
Zalucha EM, Hutch CR, Bethea M, Cook TM, Unadkat A, Wells KL, Kim KS, Maerz B, Lehrke M, Singer K, Sandoval DA. The Role of Pancreatic Preproglucagon in Regulating Local Inflammation in Mice. Cells. 2026 Mar 06; 15(5).
-
Lehenbauer KS, Nelson AJ, Nodari S, Sverdlov AL, Harrington J. The impact of oral semaglutide on cardiovascular events in patients with type 2 diabetes: review of results from the SOUL trial. Heart Fail Rev. 2025 Dec 10; 31(1):11.
-
Pruijm M, Belmar N, Bjornstad P, Cherney DZI, Das V, Gunnarsson T, Hodgin JB, Schytz PA, Tuttle KR, Kretzler M. REMODELing mechanistic trials for kidney disease: a multimodal, tissue-centered approach to understand the renal mechanism of action of semaglutide. Kidney Int. 2026 Jan; 109(1):6-16.
-
Cherney DZI, Belmar N, Bjornstad P, Chacko MM, Gunnarsson TP, Hodgin JB, Kretzler M, Pruijm M, Schytz PA, Tuttle KR. Rationale, design and baseline characteristics of REMODEL, a mechanism-of-action trial with semaglutide in people with type 2 diabetes and chronic kidney disease. Nephrol Dial Transplant. 2025 Oct 30; 40(11):2182-2192.
-
Derington CG, Sarwal A, Wei G, Hartsell SE, Throolin M, Singh R, Nevers MR, Zhang C, Katkam N, Takyi A, Chakravartula AR, Babu P, Deshmukh VG, Boucher RE, Drakos SG, Greene T, Shen J, Beddhu S. Liraglutide vs Semaglutide vs Dulaglutide in Veterans With Type 2 Diabetes. JAMA Netw Open. 2025 Oct 01; 8(10):e2537297.
-
Bethea M, Cook T, Mommandi M, McClennan A, Martin A, Hendrix JJ, Hutch CR, Lewis A, Seeley RJ, Fenselau H, da Silva Teixeria S, Sandoval DA. Weight loss reverses obesity-associated impairments in acute gastrointestinal stretch-induced suppression of food intake and glucose homeostasis. Mol Metab. 2025 Dec; 102:102260.
-
Rasouli N, Guder Arslan E, Catarig AM, Houlind K, Ludvik B, Nordanstig J, Sourij H, Thomas S, Verma S, Bonaca MP. Benefit of Semaglutide in Symptomatic Peripheral Artery Disease by Baseline Type 2 Diabetes Characteristics: Insights From STRIDE, a Randomized, Placebo-Controlled, Double-Blind Trial. Diabetes Care. 2025 Sep 01; 48(9):1529-1535.
-
Verma S, Catarig AM, Houlind K, Ludvik B, Nordanstig J, Rasouli N, Sourij H, Thomas S, Nørgaard SK, Bonaca MP. Sex Differences in Effectiveness of Semaglutide in Patients With Peripheral Artery Disease: The STRIDE Trial. J Am Coll Cardiol. 2025 Nov 18; 86(20):1843-1857.
-
Shah VN, Akturk HK, Kruger D, Ahmann A, Bhargava A, Bakoyannis G, Pyle L, Snell-Bergeon JK. Semaglutide in Adults with Type 1 Diabetes and Obesity. NEJM Evid. 2025 Aug; 4(8):EVIDoa2500173.
-
Lindsay M, Arndt G, Wieland A, Jensen T. Evolving Role of GLP-1 Therapies in Liver Disease. Curr Gastroenterol Rep. 2025 Jun 06; 27(1):36.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|